American Journal of Nephrology

Transplantation: Research Article

Oto O.A.a· Safak S.a· Mirioglu S.a,b· Yelken B.c· Velioglu A.d· Dirim A.B.a· Guller N.a· Yildiz A.e· Ersoy A.e· Turkmen A.a· Yazici H.a· Lentine K.L.f· Caliskan Y.a,f

Author affiliations

aDivision of Nephrology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey
bDivision of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey
cOrgan Transplantation Center, Koc University Hospital, Istanbul, Turkey
dDivision of Nephrology, Marmara University School of Medicine, Istanbul, Turkey
eDivision of Nephrology, Bursa Uludag University School of Medicine, Bursa, Turkey
fCenter for Abdominal Transplantation, Saint Louis University, St. Louis, MO, USA

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: August 16, 2022
Accepted: September 13, 2022
Published online: November 08, 2022

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 3

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: https://www.karger.com/AJN

Abstract

Introduction: Data to guide the evaluation of living-related donor candidates for kidney transplant recipients with Alport syndrome (AS) spectrum are limited. We aimed to examine a cohort of living-related donors to recipients with AS and compare their outcomes with a control group to improve understanding of the clinical course and outcomes of living donation in this context. Methods: Living donors (LDs) of AS recipients and propensity score-matched control LDs without any family history of AS (control group) were followed for major cardiac events, death, post-donation estimated glomerular filtration rate (eGFR), and proteinuria. Results: There were 31 LDs (48.4% male), in whom relationship to AS recipient included mother (45.2%), father (32.3%), sibling (16.1%), grandparent (3.2%), and uncle (3.2%). Long-term outcomes over 10.0 (IQR, 3.0–15.0) years were evaluated in 25 and 25 LDs from study and control groups, respectively. During follow-up, 5 LDs (20.0%) in study group developed major cardiac event (acute coronary ischemia [n = 4] and severe congestive heart failure [n = 1]) after 5.5 (IQR, 4.5–10.3) years, whereas only 2 (8.0%) LDs in control group developed major cardiac events (p = 0.221). New-onset hypertension was higher in study group (56.0%) compared to the control group (16.0%) (p = 0.003). Three donors in study and 2 donors in control group who developed new-onset hypertension died during follow-up (p = 0.297). Major cardiac event rate was significantly higher in donors who developed hypertension after donation (0 vs. 28.0%, p < 0.001). There were no differences between study groups regarding last eGFR and proteinuria levels (p = 0.558 and p = 0.120, respectively). Discussion/Conclusion: Although the risk of kidney disease can be minimized by careful donor evaluation, our findings suggest that hypertension risk after the donation is higher than expected in related donors of recipients with AS.

© 2022 S. Karger AG, Basel

References Miner JH. Pathology vs. molecular genetics: (re)defining the spectrum of Alport syndrome. Kidney Int. 2014 Dec;86(6):1081–3. Demir E, Caliskan Y. Variations of type IV collagen-encoding genes in patients with histological diagnosis of focal segmental glomerulosclerosis. Pediatr Nephrol. 2020 Jun;35(6):927–36. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020 Aug 18;173(4):268–77. Kashtan CE. Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation. Int J Nephrol Renovasc Dis. 2018;11:267–70. Fallerini C, Baldassarri M, Trevisson E, Morbidoni V, La Manna A, Lazzarin R, et al. Alport syndrome: impact of digenic inheritance in patients management. Clin Genet. 2017 Jul;92(1):34–44. Caliskan Y, Lentine KL. Approach to genetic testing to optimize the safety of living donor transplantation in Alport syndrome spectrum. Pediatr Nephrol. 2022 Jan 27;37(9):1981–94. Kasiske BL, Ravenscraft M, Ramos EL, Gaston RS, Bia MJ, Danovitch GM. The evaluation of living renal transplant donors: clinical practice guidelines. Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol. 1996 Nov;7(11):2288–313. Niaudet P. Living donor kidney transplantation in patients with hereditary nephropathies. Nat Rev Nephrol. 2010 Dec;6(12):736–43. Caliskan Y, Lee B, Whelan A, Abualrub F, Lentine KL, Jittirat A. Evaluation of genetic kidney diseases in living donor kidney transplantation: towards precision genomic medicine in donor risk assessment. Curr Transplant Rep. 2022 Jun;9(2):127–42. Caliskan Y, Karahan G, Akgul SU, Mirioglu S, Ozluk Y, Yazici H, et al. LIMS1 risk genotype and T cell-mediated rejection in kidney transplant recipients. Nephrol Dial Transplant. 2021 Nov 9;36(11):2120–9. Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol. 2013 Feb;24(3):364–75. Peten E, Pirson Y, Cosyns JP, Squifflet JP, Alexandre GP, Noël LH, et al. Outcome of thirty patients with Alport’s syndrome after renal transplantation. Transplantation. 1991 Nov;52(5):823–6. Göbel J, Olbricht CJ, Offner G, Helmchen U, Repp H, Koch KM, et al. Kidney transplantation in Alport’s syndrome: long-term outcome and allograft anti-GBM nephritis. Clin Nephrol. 1992 Dec;38(6):299–304. Kashtan CE, McEnery PT, Tejani A, Stablein DM. Renal allograft survival according to primary diagnosis: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol. 1995 Dec;9(6):679–84. Byrne MC, Budisavljevic MN, Fan Z, Self SE, Ploth DW. Renal transplant in patients with Alport’s syndrome. Am J Kidney Dis. 2002 Apr;39(4):769–75. Temme J, Kramer A, Jager KJ, Lange K, Peters F, Müller GA, et al. Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. Clin J Am Soc Nephrol. 2012 Dec;7(12):1969–76. Yilmaz VT, Dinckan A, Yilmaz F, Suleymanlar G, Kocak H. Outcomes of renal transplantation in patients with Alport syndrome. Transplant Proc. 2015 Jun;47(5):1377–81. Gillion V, Dahan K, Cosyns JP, Hilbert P, Jadoul M, Goffin E, et al. Genotype and outcome after kidney transplantation in Alport syndrome. Kidney Int Rep. 2018 May;3(3):652–60. Kashtan CE. Alport syndrome: achieving early diagnosis and treatment. Am J Kidney Dis. 2021 Feb;77(2):272–9. Choi BG, Rha SW, Yoon SG, Choi CU, Lee MW, Kim SW. Association of major adverse cardiac events up to 5 years in patients with chest pain without significant coronary artery disease in the Korean population. J Am Heart Assoc. 2019 Jun 18;8(12):e010541. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604–12. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405–24. Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245–57. Sanchez OA, Ferrara LK, Rein S, Berglund D, Matas AJ, Ibrahim HN. Hypertension after kidney donation: incidence, predictors, and correlates. Am J Transplant. 2018 Oct;18(10):2534–43. Munch P, Christiansen CF, Birn H, Erikstrup C, Nørgaard M. Is the risk of cardiovascular disease increased in living kidney donors? A Danish population-based cohort study. Am J Transplant. 2021 May;21(5):1857–65. Caliskan Y, Yildiz A. Evaluation of the medically complex living kidney donor. J Transplant. 2012;2012:450471. Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA. KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Transplantation. 2017 Aug;101(8S Suppl 1):S1–109. Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int. 2003 Feb;63(2):438–46. Gross O, Tönshoff B, Weber LT, Pape L, Latta K, Fehrenbach H, et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int. 2020 Jun;97(6):1275–86. Gross O, Weber M, Fries JWU, Muller GA. Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome. Nephrol Dial Transplant. 2009 May;24(5):1626–30. Savige J, Lipska-Zietkiewicz BS, Watson E, Hertz JM, Deltas C, Mari F, et al. Guidelines for genetic testing and management of Alport syndrome. Clin J Am Soc Nephrol. 2022 Jan;17(1):143–54. Gibson J, Fieldhouse R, Chan MMY, Sadeghi-Alavijeh O, Burnett L, Izzi V, et al. Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol. 2021 Sep;32(9):2273–90. Article / Publication Details

First-Page Preview

Received: August 16, 2022
Accepted: September 13, 2022
Published online: November 08, 2022

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 3

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: https://www.karger.com/AJN

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.